Bicara Therapeutics Inc. Common Stock
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-28.77 | -335.61 | -91.43% | -13.94 | +106.35% |
| P/S |
|
0 | 28.76 | -100% |
|
|
| P/BV |
|
5.95 | -1320.1 | -100.45% |
|
|
| P/FCF |
|
-26.14 | -115.29 | -77.32% |
|
|
| Ev/Ebitda |
|
-35.99 | -870.14 | -95.86% |
|
|
| Ev/S |
|
0 | 10.85 | -100% |
|
|
| Ev/FCF |
|
-32.59 | -557.05 | -94.15% |
|
|
| E/P |
|
-0.0348 | -0.0029 | 1083.41% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 7.51 | -100% | 0 | 0% |
| ROE |
|
-39.63 | 253.66 | -115.63% |
|
|
| ROA |
|
-18.28 | -37.56 | -51.34% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
0 | 6.59 | -100% |
|
|
| ROCE |
|
-13.79 | 3.51 | -492.88% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0109 | 0.0832 | -113.09% | -0.0118 | -7.74% |
| Nеt Debt/Ebitda |
|
7.22 | -0.56 | -1399.06% |
|
|
| Debt/Ratio |
|
0.0014 | 0.0669 | -97.84% |
|
|
| Debt/Equity |
|
0.0368 | -1.1 | -103.36% |
|
|
| Debt/Net Income |
|
-0.0109 | -0.0264 | -58.94% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0 | 0% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0 | 0% | ||
| DSI |
|
0 | 0 | 0% |
|
|
| Average dividend growth |
|
0 | 0 | 0% |
|
|
| Average percentage for 5 years |
|
0 | 0 | 0% |
|
|
| Average percentage for payments |
|
0 | 0 | 0% |
|
|
| Difference from average difference in sector |
|
0 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 294.53 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
118.26 | 787.75 | -84.99% | ||
| Growth impulse Net Income in 5 years |
|
79.67 | 177.33 | -55.07% | ||
| Growth impulse FCF in 5 years |
|
131.88 | -74.43 | -277.19% | ||
| Growth impulse EPS in 5 years |
|
-49.03 | -195.95 | -74.98% |
IP Score
3/10
